Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
Several studies have examined the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia. As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied. In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [(11)C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls versus patients with schizophrenia. A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [(11)C]OMAR. The CB1 binding (expressed as the distribution volume; V(T)) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia. Controls showed a correlation with the known distribution of CB1 and decline of [(11)C]OMAR binding with age, most significantly in the globus pallidus. Overall, we observed elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p<0.05), by the Students t-test. When we ran a regression of the control subjects V(T) values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals. There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores (r=0.49), but there was a significant correlation between V(T) and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r=0.60), and middle and posterior cingulate regions (r=0.71 and r=0.79 respectively). In conclusion, we found that [(11)C] OMAR can image human CB1 receptors in normal aging and schizophrenia. In addition, our initial data in subjects with schizophrenia seem to suggest an association of elevated binding specific brain regions and symptoms of the disease.
Wong
Dean F
DF
Radiology, Johns Hopkins University, Baltimore, MD 21287, USA. dfwong@jhmi.edu
Kuwabara
Hiroto
H
Horti
Andrew G
AG
Raymont
Vanessa
V
Brasic
James
J
Guevara
Maria
M
Ye
Weiguo
W
Dannals
Robert F
RF
Ravert
Hayden T
HT
Nandi
Ayon
A
Rahmim
Arman
A
Ming
Jeffrey E
JE
Grachev
Igor
I
Roy
Christine
C
Cascella
Nicola
N
D000328:Adult; D001921:Brain / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D011720:Pyrazoles / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000378:metabolism*; D014018:Tissue Distribution
C515663:4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; D010880:Piperidines; D011720:Pyrazoles; D019275:Radiopharmaceuticals; D043884:Receptor, Cannabinoid, CB1
Hum Brain Mapp. 2008 Apr;29(4):478-89
17525988
Neuropsychopharmacology. 2008 Jan;33(2):259-69
17392732
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
2308954
Pharmacogenomics J. 2007 Aug;7(4):275-81
16983399
Addict Biol. 2008 Jun;13(2):147-59
18482430
Neuropsychopharmacology. 2004 Nov;29(11):2108-14
15354183
Psychopharmacology (Berl). 2009 Oct;206(2):313-24
19652957
J Nucl Med. 2008 Mar;49(3):439-45
18287275
J Neural Transm (Vienna). 2007;114(8):1055-63
17370106
Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):413-31
19609589
Neuroscience. 2001;103(1):9-15
11311783
Biol Psychiatry. 2005 Mar 15;57(6):594-608
15780846
Am J Epidemiol. 2002 Aug 15;156(4):319-27
12181101
Neuroimage. 2008 Feb 15;39(4):1533-41
18077184
Arch Gen Psychiatry. 2009 Feb;66(2):196-204
19188542
Arch Gen Psychiatry. 2007 May;64(5):532-42
17485605
BMJ. 2002 Nov 23;325(7374):1212-3
12446537
Lancet. 1987 Dec 26;2(8574):1483-6
2892048
Med Res Rev. 2009 Mar;29(2):213-71
18777572
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9800-5
17535893
Neuroimage. 2002 Jan;15(1):273-89
11771995
Neuroimage. 2009 Nov 1;48(2):362-70
19573609
Neuroendocrinology. 2010;91(2):155-68
19815998
J Nucl Med. 2006 Oct;47(10):1689-96
17015906
Int J Neuropsychopharmacol. 2008 Sep;11(6):827-35
18257959
Neuroscience. 1997 Mar;77(2):299-318
9472392
Neuroimage. 2006 Nov 15;33(3):843-54
16996751
Phys Med Biol. 2005 Oct 21;50(20):4887-912
16204879
Arch Gen Psychiatry. 2008 Jul;65(7):772-84
18606950
Neuro Endocrinol Lett. 2009;30(2):153-79
19675519
Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):279-84
18186055
BMJ. 2002 Nov 23;325(7374):1199
12446534
Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):428-33
15995876
J Neurosci. 2001 Apr 1;21(7):2425-33
11264316
Eur J Neurosci. 2003 Dec;18(11):3134-44
14656310
Exp Brain Res. 2006 Jul;172(4):556-60
16710682
Trends Cogn Sci. 2000 Jun;4(6):215-222
10827444
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
14751433
BMJ. 2005 Jan 1;330(7481):11
15574485
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
2384545
Arch Gen Psychiatry. 1992 Mar;49(3):246
1567279
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135
PLoS One. 2008 Feb 20;3(2):e1640
18286196
Mol Psychiatry. 2002;7(5):515-8
12082570
Neuroreport. 1999 Jun 3;10(8):1665-9
10501554
Prog Brain Res. 2005;150:205-17
16186025
Eur J Neurosci. 2003 May;17(9):1747-54
12752773
Int Rev Neurobiol. 2007;78:289-326
17349865
Curr Pharm Des. 2008;14(31):3363-83
19075713
Psychiatry Res. 2006 Oct 30;147(2-3):249-56
16919917
Nucl Med Biol. 2000 Aug;27(6):627-30
11056380
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
17519979
Int J Addict. 1986 Apr-May;21(4-5):579-87
3021637